LOS ANGELES, June 01, 2023 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is proud to announce the recipients of…
SAB Biotherapeutics President & Chief Executive Officer Eddie Sullivan, Ph.D. to present novel DiversitAb™ platform pipeline, with emphasis on partnering…
First subject dosed in Phase 1 trial of PYX-106, a fully human immunotherapy antibody candidate Second dose level initiated in…
Results Add to Growing Body of Evidence that Inhibiting PP2A with LB-100 May Be a General Method for Enhancing the Effectiveness of…
New data show continued durability of response over 14 months with humoral immune responses increasing over time LAWRENCEVILLE, N.J., May…
Media Release Appointment of Charles River Laboratories ("Charles River") to run Immutep’s preclinical toxicology study evaluating the safety and toxicity…
AUSTIN, Texas, May 26, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company…
NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical…
Media Release New data published from Part C of TACTI-002 Phase II Trial evaluating eftilagimod alpha plus pembrolizumab in metastatic…
Basel, 26 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will be presenting new data on six approved and…